作者: Antarctic 時(shí)間: 2025-3-21 23:39 作者: 凌辱 時(shí)間: 2025-3-22 03:09
Book 2019oplasms arising within the gastrointestinal tract. The causative gene of this disease was originally discovered in Japan by Prof. Seichi Hirota in 1998, and since then numerous important advances – from basic to clinical aspects – have been reported from Japan. Professionals involved in the manageme作者: 窩轉(zhuǎn)脊椎動(dòng)物 時(shí)間: 2025-3-22 05:58
https://doi.org/10.1007/978-3-662-00599-6red as at least some malignancy (labeled as /1 or /3 in the behavior code of ICD-O-3). We do not know how many cases are there that are considered as benign. Some summaries of the current status of GIST treatment are provided using the same dataset.作者: 偶然 時(shí)間: 2025-3-22 09:24
,Modellrechnung zur Chemie der Atmosph?re,n is recommended for imatinib-resistant GISTs. Regorafenib should be considered in patients with imatinib or sunitinib-resistant GISTs. During these tyrosine kinase therapies, surgery should be considered if feasible.作者: Grasping 時(shí)間: 2025-3-22 16:38
Epidemiology,red as at least some malignancy (labeled as /1 or /3 in the behavior code of ICD-O-3). We do not know how many cases are there that are considered as benign. Some summaries of the current status of GIST treatment are provided using the same dataset.作者: Grasping 時(shí)間: 2025-3-22 18:51
Treatment Guidelines,n is recommended for imatinib-resistant GISTs. Regorafenib should be considered in patients with imatinib or sunitinib-resistant GISTs. During these tyrosine kinase therapies, surgery should be considered if feasible.作者: decode 時(shí)間: 2025-3-22 22:25 作者: 痛打 時(shí)間: 2025-3-23 03:56
First-Line Treatment,ct of imatinib is the trough level of imatinib. Although the treatment results improved, primary resistant cases, in which the effect of imatinib cannot be expected from the beginning, and secondary resistant cases, in which the effect was exhibited at the beginning but resistance was exhibited later, have become problematic.作者: 無(wú)法治愈 時(shí)間: 2025-3-23 09:03 作者: delusion 時(shí)間: 2025-3-23 10:32
Histology,a of the gastrointestinal tract has become a very rare entity in the “KIT” era. Both histopathological procedures and molecular investigations are important for the evolution of diagnosis and treatment of GIST and mimics.作者: 類人猿 時(shí)間: 2025-3-23 15:12 作者: 期滿 時(shí)間: 2025-3-23 21:13
Risk Classification,ication systems, the modified NIH criteria appear to be the best for selecting patients for whom postoperative adjuvant imatinib is indicated; however, even these criteria have some limitations and outstanding issues. Further studies aimed at improving available risk-stratification systems and thus 作者: 濃縮 時(shí)間: 2025-3-24 01:40
Surgery,e spared and a proximal gastrectomy can be avoided. The application of LECS was used on lesions that did not include any mucosal lesions since the gastric wall was opened. However, it also became possible to perform a resection on GISTs with ulcerated lesions without scattering tumor cells inside th作者: enormous 時(shí)間: 2025-3-24 03:18
Adjuvant and Neoadjuvant Treatment, Neoadjuvant treatment is a promising strategy for marginally resectable GISTs, but the prospective comparison of adjuvant and neoadjuvant therapy for such patients has not been performed. The further accumulation of evidence and the establishment of universal risk estimation and prevalence of genot作者: 搜尋 時(shí)間: 2025-3-24 09:22
Book 2019specially focusing on the highly valuable data from Japan. This attractive collection benefits not only oncologists but also basic researchers, general physicians and surgeons, as well as paramedical staff and medical students who aredealing with GISTs..作者: chemical-peel 時(shí)間: 2025-3-24 11:44
https://doi.org/10.1007/978-3-662-63780-7a of the gastrointestinal tract has become a very rare entity in the “KIT” era. Both histopathological procedures and molecular investigations are important for the evolution of diagnosis and treatment of GIST and mimics.作者: 跳脫衣舞的人 時(shí)間: 2025-3-24 17:48 作者: jungle 時(shí)間: 2025-3-24 20:51 作者: 燈絲 時(shí)間: 2025-3-25 00:17
https://doi.org/10.1007/978-3-662-02258-0e spared and a proximal gastrectomy can be avoided. The application of LECS was used on lesions that did not include any mucosal lesions since the gastric wall was opened. However, it also became possible to perform a resection on GISTs with ulcerated lesions without scattering tumor cells inside th作者: 出汗 時(shí)間: 2025-3-25 03:46
Funktionelle Grundlagen der Atmung, Neoadjuvant treatment is a promising strategy for marginally resectable GISTs, but the prospective comparison of adjuvant and neoadjuvant therapy for such patients has not been performed. The further accumulation of evidence and the establishment of universal risk estimation and prevalence of genot作者: 匯總 時(shí)間: 2025-3-25 07:35
nosis, and treatment of GISTs, especially focusing on the highly valuable data from Japan. This attractive collection benefits not only oncologists but also basic researchers, general physicians and surgeons, as well as paramedical staff and medical students who aredealing with GISTs..978-981-13-3206-7作者: 變白 時(shí)間: 2025-3-25 15:31 作者: 并排上下 時(shí)間: 2025-3-25 18:58
https://doi.org/10.1007/978-3-662-00599-6that examined stomach specimen from autopsy or surgery of other diseases suggest that there may be occult GISTs. The distinction between benign and malignant cases is also ambiguous. Cancer registries may not be a reliable source because many limit the reportability of the tumor into only malignant 作者: Custodian 時(shí)間: 2025-3-25 21:35
https://doi.org/10.1007/978-3-662-63780-7r-targeted therapy of gastrointestinal mesenchymal tumors. According to a recent concept, GIST is considered a spindle or epithelioid cell neoplasm which basically expresses KIT protein and has . or . gene mutation. Exceptional cases are immunohistochemically negative or weakly positive for KIT (oft作者: 財(cái)政 時(shí)間: 2025-3-26 00:21
Atmosph?rische Ausbreitungsmodellierungported to cause ligand-independent constitutive activation of receptor tyrosine kinase, KIT and PDGFR-α, and subsequently activate common downstream signaling pathways, including ERK kinases, PI3kinase-mTOR pathways, and STATs pathways. These mutations have been reported to be related with various c作者: Jingoism 時(shí)間: 2025-3-26 07:12 作者: Anthrp 時(shí)間: 2025-3-26 09:49
,Modellrechnung zur Chemie der Atmosph?re,y small GISTs (<2?cm) without high-risk features on endoscopic ultrasonography can be placed under observation. For other resectable GISTs, complete resection should be initially considered. Postoperative imatinib administration for at least 36?months should be considered in patients with a signific作者: 做方舟 時(shí)間: 2025-3-26 12:41 作者: 人類的發(fā)源 時(shí)間: 2025-3-26 18:51
K. Amersbach,G. Bayer,R. Staehelincurrent GIST, with a handful of patients surviving without progression for longer than 10?years. The most important predictive factor of the effect of imatinib is a c-kit gene mutation, with a gene mutation of EXON11 being a good prognostic factor. In addition to this, the factor related to the effe作者: 忘川河 時(shí)間: 2025-3-26 23:30 作者: 平 時(shí)間: 2025-3-27 04:29
Funktionelle Grundlagen der Atmung,ressing high-risk features, such as large tumors or tumors with a high mitotic rate, are likely to develop recurrence with distant metastasis. In the past two decades, tyrosine kinase inhibitors were introduced for the treatment of GIST, and imatinib greatly prolonged the survival of metastatic or u作者: pulmonary-edema 時(shí)間: 2025-3-27 08:27
https://doi.org/10.1007/978-3-642-91718-9ecular targeted therapy (imatinib, sunitinib, and regorafenib). Developmental therapeutics for GIST is focused on primary or acquired resistance to these agents. In this section, we discuss new agents for the treatment of GIST.作者: CRANK 時(shí)間: 2025-3-27 11:09
Depositionsmessungen im Land Brandenburg,GIST is the most frequent mesenchymal tumor in the digestive tract. Imaging modalities comprising of ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography/computed tomography (PET/CT) are routinely used for management of tumor. We focus on diagnosis of staging, recurrence, and monitoring.作者: HAWK 時(shí)間: 2025-3-27 14:29
Diagnostic Imaging of Gastrointestinal Stromal Tumor,GIST is the most frequent mesenchymal tumor in the digestive tract. Imaging modalities comprising of ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography/computed tomography (PET/CT) are routinely used for management of tumor. We focus on diagnosis of staging, recurrence, and monitoring.作者: panorama 時(shí)間: 2025-3-27 19:48
Yukinori Kurokawa,Yoshito KomatsuEnriches our understanding of GISTs both from basic to clinical aspects.Collects unique and cutting-edge data from the Asian region.Provides a comprehensive update of GISTs作者: 有法律效應(yīng) 時(shí)間: 2025-3-27 23:16 作者: Mercantile 時(shí)間: 2025-3-28 06:09
New Agents for Gastrointestinal Stromal Tumors,ecular targeted therapy (imatinib, sunitinib, and regorafenib). Developmental therapeutics for GIST is focused on primary or acquired resistance to these agents. In this section, we discuss new agents for the treatment of GIST.作者: Obstreperous 時(shí)間: 2025-3-28 09:55
Springer Nature Singapore Pte Ltd. 2019作者: fastness 時(shí)間: 2025-3-28 13:50 作者: 原諒 時(shí)間: 2025-3-28 18:31 作者: 忍耐 時(shí)間: 2025-3-28 21:06 作者: antidepressant 時(shí)間: 2025-3-29 01:13 作者: anagen 時(shí)間: 2025-3-29 04:41 作者: Coterminous 時(shí)間: 2025-3-29 08:14
Surgery,ve the tumor without damaging the pseudocapsule. Removal of the lymph nodes is usually not necessary..Normally a laparoscopic excision is used on lesions under 5 cm. When using the magnification from a laparoscope, the blood vessels that are manipulated are held to a minimum and the nerves can be pr作者: Intercept 時(shí)間: 2025-3-29 12:17
First-Line Treatment,current GIST, with a handful of patients surviving without progression for longer than 10?years. The most important predictive factor of the effect of imatinib is a c-kit gene mutation, with a gene mutation of EXON11 being a good prognostic factor. In addition to this, the factor related to the effe作者: 天賦 時(shí)間: 2025-3-29 16:12
Second- and Third-Line Treatment,has been identified as a potent inhibitor of VEGFR-1, VEGFR-2, fetal liver tyrosine kinase receptor 3 (FLT3), KIT (stem-cell factor [SCF] receptor), PDGFRα, and PDGFR. Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions作者: 植物學(xué) 時(shí)間: 2025-3-29 20:10
Adjuvant and Neoadjuvant Treatment,ressing high-risk features, such as large tumors or tumors with a high mitotic rate, are likely to develop recurrence with distant metastasis. In the past two decades, tyrosine kinase inhibitors were introduced for the treatment of GIST, and imatinib greatly prolonged the survival of metastatic or u作者: 謊言 時(shí)間: 2025-3-30 02:15
New Agents for Gastrointestinal Stromal Tumors,ecular targeted therapy (imatinib, sunitinib, and regorafenib). Developmental therapeutics for GIST is focused on primary or acquired resistance to these agents. In this section, we discuss new agents for the treatment of GIST.作者: neologism 時(shí)間: 2025-3-30 06:31 作者: 傳染 時(shí)間: 2025-3-30 11:55
https://doi.org/10.1007/978-3-319-78667-4MSC (2010): 01A55, 01A60, 01A70, 01A74; Giovanni Battista Guccia; Circolo Matematico di Palermo; beginn
